QUIA PHARMA AB (FRA:99B0) Days Payable: 3,513.13 (As of Jun. 2025) — 4218% Above Median


What is QUIA PHARMA AB Days Payable?

QUIA PHARMA AB FRA:99B0 Days Payable is 3,513.13 as of Jun. 2025, which is 4218% above its 10-year median of 81.36. The stock has 3 warning signs investors should review.

QUIA PHARMA AB's average Accounts Payable for the six months ended in Jun. 2025 was €0.42 Mil. QUIA PHARMA AB's Cost of Goods Sold for the six months ended in Jun. 2025 was €0.02 Mil. Hence, QUIA PHARMA AB's Days Payable for the six months ended in Jun. 2025 was 3,513.13.

The historical rank and industry rank for QUIA PHARMA AB's Days Payable or its related term are showing as below:

During the past 13 years, QUIA PHARMA AB's highest Days Payable was 786.15. The lowest was 65.49. And the median was 81.36.

FRA:99B0's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

QUIA PHARMA AB's Days Payable declined from Jun. 2024 (5,545.97) to Jun. 2025 (3,513.13). It may suggest that QUIA PHARMA AB accelerated paying its suppliers.

QUIA PHARMA AB Days Payable Historical Data

* Premium members only.

The historical data trend for QUIA PHARMA AB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

QUIA PHARMA AB Days Payable Chart

QUIA PHARMA AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.66 0.00 0.00 0.00 0.00

QUIA PHARMA AB Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 5,545.97 0.00 3,513.13

FRA:99B0 vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, QUIA PHARMA AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

QUIA PHARMA AB Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QUIA PHARMA AB's Days Payable distribution charts can be found below:

* The bar in red indicates where QUIA PHARMA AB's Days Payable falls into.


QUIA PHARMA AB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

QUIA PHARMA AB's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

Days Payable (A: Dec. 2024 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2023 ) + Accounts Payable (A: Dec. 2024 )) / count ) / Cost of Goods Sold (A: Dec. 2024 )*Days in Period
=( (0.284 + 0.328) / 2 ) / -0.029*365
=0.306 / -0.029*365
=N/A

QUIA PHARMA AB's Days Payable for the quarter that ended in Jun. 2025 is calculated as:

Days Payable (Q: Jun. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2024 ) + Accounts Payable (Q: Jun. 2025 )) / count ) / Cost of Goods Sold (Q: Jun. 2025 )*Days in Period
=( (0.328 + 0.519) / 2 ) / 0.022*365 / 2
=0.4235 / 0.022*365 / 2
=3,513.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 3,513.13 mean?
QUIA PHARMA AB (FRA:99B0) has a Days Payable of 3,513.13 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on QUIA PHARMA AB and its competitors. This is 4218% above median its historical median of 81.36. Over the past decade, QUIA PHARMA AB's Days Payable has ranged from 65.49 to 786.15.
Is QUIA PHARMA AB's Days Payable too high?
QUIA PHARMA AB's current Days Payable of 3,513.13 is 4218% above median its 10-year median of 81.36. Over the past 10 years, this metric has ranged from a low of 65.49 to a high of 786.15. The Biotechnology industry median Days Payable is 113.56. QUIA PHARMA AB's value of 3,513.13 is 2993.6% above this industry median.
How does QUIA PHARMA AB's Days Payable compare to VRTX and REGN?
QUIA PHARMA AB's Days Payable of 3,513.13 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.56. QUIA PHARMA AB's value of 3,513.13 is 2993.6% above this benchmark. Historically, QUIA PHARMA AB's own Days Payable has ranged from 65.49 to 786.15 over the past decade. While the company's 10-year median is 81.36 vs. the industry median of 113.56, QUIA PHARMA AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. QUIA PHARMA AB's current Days Payable of 3,513.13 is 2993.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on QUIA PHARMA AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. QUIA PHARMA AB's current Days Payable is 3,513.13, which is 4218% above median its own 10-year median of 81.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current Days Payable of 3,513.13. The current Days Payable is 3,513.13, which is 4218% above median its 10-year median of 81.36 and 2993.6% above the Biotechnology industry median of 113.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current Days Payable is 3,513.13 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

QUIA PHARMA AB Business Description

Address Virdings Alle 32 B, Uppsala, SWE, 754 50
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.